ICU Medical (NASDAQ:ICUI) Given New $182.00 Price Target at KeyCorp

ICU Medical (NASDAQ:ICUI) had its price objective hoisted by KeyCorp from $164.00 to $182.00 in a research report sent to investors on Tuesday morning, MarketBeat.com reports. They currently have an overweight rating on the medical instruments supplier’s stock.

A number of other equities analysts have also recently commented on the stock. Piper Sandler cut their target price on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Zacks Research upgraded shares of ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Weiss Ratings upgraded shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. BTIG Research started coverage on shares of ICU Medical in a research report on Monday, June 15th. They set a “buy” rating and a $170.00 price objective on the stock. Finally, Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ICU Medical presently has a consensus rating of “Buy” and an average target price of $172.00.

ICU Medical Stock Up 0.9%

Shares of NASDAQ ICUI opened at $158.77 on Tuesday. The business has a 50-day moving average price of $142.12 and a 200 day moving average price of $139.41. The stock has a market cap of $3.97 billion, a PE ratio of 85.82, a price-to-earnings-growth ratio of 2.20 and a beta of 0.76. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. ICU Medical has a 52-week low of $107.00 and a 52-week high of $162.85.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping the consensus estimate of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The company had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. During the same quarter in the previous year, the company posted $1.72 earnings per share. The firm’s revenue was down 12.3% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities research analysts forecast that ICU Medical will post 6.51 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David C. Greenberg sold 2,424 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the sale, the director directly owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Institutional investors have recently bought and sold shares of the company. Hilton Head Capital Partners LLC acquired a new stake in shares of ICU Medical in the 4th quarter worth $32,000. Covestor Ltd boosted its holdings in shares of ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 126 shares in the last quarter. Strs Ohio increased its stake in shares of ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after acquiring an additional 300 shares during the period. Rockefeller Capital Management L.P. increased its stake in shares of ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 146 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in ICU Medical during the fourth quarter worth about $120,000. 96.10% of the stock is owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.